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administered acetylsalicylic acid in the isolated
perfused equine distal limb
Maren Friebe*, Stephan Schumacher, Jessica Stahl and Manfred KietzmannAbstract
Background: This study investigated synovial concentrations of acetylsalicylic acid (ASA) and its metabolite salicylic
acid (SA) in the equine fetlock joint following systemic administration of ASA. Salicylates were chosen because SA is
the only nonsteroidal anti-inflammatory drug for which threshold levels exist for plasma and urine in equine sports.
To avoid animal experiments, the study was conducted using an ex vivo model of the isolated perfused equine
distal limb in combination with plasma concentrations obtained from literature.
Salicylate concentrations in the joint were determined using microdialysis and high performance liquid
chromatography (HPLC). Any anti-inflammatory effect of synovial ASA concentrations was assessed using an ASA
EC50 (half maximal effective concentration) determined in equine whole blood.
Results: The ASA concentration in the synovial fluid (n = 6) reached a maximum of 4 μg/mL, the mean
concentration over the entire perfusion period was 2 μg/mL. Maximum SA concentration was 17 μg/mL, the
average was 14 μg/mL. ASA and SA concentration in the synovial fluid exceeded systemic concentrations 2 h and
3.5 h after “systemic” administration, respectively.
Conclusions: ASA and SA accumulated in the in the synovial fluid of the ex vivo model despite decreasing systemic
concentrations. This suggests a prolonged anti-inflammatory effect within the joint that remains to be further
elucidated.
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Acetylsalicylic acid (ASA) belongs to the group of non-
steroidal anti-inflammatory drugs (NSAIDs) and is rap-
idly converted to its metabolite salicylic acid (SA) after
administration. In horses, ASA is not routinely used for
the treatment of inflammatory conditions because of its
short half-life, low potency and resulting high dosages
needed [1-3]. Still, ASA and SA pharmacokinetics are of
interest because SA is the only NSAID with threshold
levels for plasma and urine in equine sports [4-6]. These
threshold levels have been introduced to avoid positive
cases due to salicylates originating from plants poten-
tially present in equine feed, e.g. in alfalfa hay [7]. How-
ever, threshold levels might increase the risk of ASA* Correspondence: maren.friebe@tiho-hannover.de
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reproduction in any medium, provided the orbeing abused for therapeutic purposes up to the thresh-
old in competition horses [8]. In this context, we were
interested in synovial fluid concentrations after systemic
administration because none of the numerous studies
that have dealt with salicylate pharmacokinetics in
humans [9-11], cattle [12], and horses [1,3] has so far ex-
plored the distribution of ASA or SA into joint fluid.
Therefore, the study presented aimed to investigate to
what extent ASA is distributed into the synovial fluid of
horses after systemic administration.
To avoid ethical limitations arising from the use of
study horses and to minimize costs, an ex vivo model
of the isolated perfused equine distal limb recently
established in our group was used [13]. Imitating sys-
temic application of ASA in this model was possible be-
cause plasma concentrations of ASA and SA were
readily available from an in vivo study investigating ASA
pharmacokinetics in horses [1].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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trations were monitored using the microdialysis tech-
nique. This involves placement of a tubular microdialysis
probe into the synovial cavity: the probe comprises a
semi-permeable membrane and is constantly perfused
with a physiological buffer solution, the so-called perfus-
ate, at a low flow rate. Unbound drug molecules present
in the synovial fluid will diffuse through the semi-
permeable membrane into the perfusate, down their
concentration gradient. Larger molecules, such as pro-
teins and enzymes, cannot cross the membrane. How-
ever, an equilibrium between the perfusate and the
periprobe fluid will never be reached because of the per-
fusate’s constant movement. The concentration of the an-
alyte in the perfusate will therefore always be less than in
the periprobe fluid. The ratio between these concentra-
tions is defined as relative recovery (RR) and needs to be
determined for each probe in vitro in order to correctly
interpret concentrations measured in the perfusate. The
microdialysis technique has already been applied for sam-
pling of SA in skin-penetration studies [14-16].
To get some orientation concerning the effect of
plasma protein binding on the synovial distribution of
ASA and SA, the experiment was repeated with autolo-
gous, diluted blood as perfusate, referred to as hemo-
perfusion experiments throughout this paper.
Methods
Isolated perfused equine distal limb
Tyrode perfusion
Six limbs from six different horses were used for this
study; each limb was used for one experiment. The prep-
aration of the limb model was performed as described
previously [13]. In brief, distal limbs of warmblood
horses of various sex and age were obtained from a
slaughterhouse where they were exarticulated in the
middle carpal joint within a maximum of 30 min after
slaughter. Immediately afterwards, the median artery
was canulated and infused with heparinised (120 IU/mL;
Euro OTC Pharma GmbH, Bönen, Germany) tyrode
solution (136.8 mmol/L NaCl, 2.7 mmol/L KCl, 1.8
mmol/L CaCl2 × 2H2O, 1.05 mmol/L MgCl2 × 6H2O,
0.416 mmol/L NaH2PO4 × 2H2O, 11.9 mmol/L NaHCO3
and 5.5 mmol/L D(+)-glucose × 1H2O) to prevent clot
formation in the vessels. Extremities were transported to
the laboratory and perfused with oxygenated (carbogen:
95% oxygen and 5% carbon dioxide) tyrode solution
containing sodium carboxymethyl cellulose (0.15 g/L,
Caesar & Loretz, Hilden, Germany) to increase the
oncotic pressure in the vessels and therefore counteract
edema formation. Perfusion occurred via the median ar-
tery over a period of 8 h, during which the flow rate of
approximately 65 mL/min was upheld by a peristaltic
pump (Masterflex 7553–76; Cole-Palmer InstrumentsCo, Vernon Hills, IL, USA). The temperature of the per-
fusion fluid was maintained at 37°C by a water bath. Per-
fusion started within 60 min after slaughter.
Tissue viability was assessed for each extremity
throughout the perfusion period as follows: perfusate
samples were taken from the radial vein after 4 h and
8 h of perfusion to determine glucose utilization, lactate
production, and lactate dehydrogenase (LDH) release.
Furthermore, the skin surface temperature was mea-
sured in hourly intervals. The extremity’s weight was
recorded before and after the experiment to assess
edema formation. Based on results published earlier
[13], the following requirements for tissue viability were
to be fulfilled by isolated perfused limbs in order to be
regarded as viable and therefore evaluable:
1. Glucose utilization ≥ 200 mg/h
2. Lactate production ≤ 400 mg/h
3. LDH activity ≤ 10 U/h
4. Skin surface temperature ≥ 26°C
Hemoperfusion
After conclusion of the tyrode perfusion experiments,
two extremities of different horses were perfused with
diluted autologous blood in order to give a rough over-
view of the influence of plasma protein binding on the
synovial distribution of ASA and SA. The duration of
perfusion was reduced to 5 h because this was the
period in which the main concentration changes had oc-
curred in the precedent tyrode perfusion experiments.
For hemoperfusion, extremities were prepared as de-
scribed above. In addition, 10 L of autologous blood
were collected during exsanguination; anticoagulation
was achieved with heparin (18 IU/mL). After transport
to the laboratory, the extremity was connected to the
perfusion system via the median artery and perfused
with tyrode solution for 30 min to remove all remaining
blood in the vessels. In accordance with Bäumer et al.
[17], the leg was subsequently perfused with a blood-
tyrode mixture (4:1) referred to as hemoperfusion
perfusate in an open perfusion system. The blood was
oxygenated by means of the counter-current-principle
with a dialyser (DiacapW hollow fiber dialyser, Braun
AG, Melsungen, Germany), through which the hemoper-
fusion perfusate and 8 L of tyrode solution gassed with
pure oxygen were pumped in opposite directions. The
tyrode solution in the dialysis circle was continuously
moved by a rotary pump (EHEIM, Deizisau, Germany)
at a speed of approximately 0.5 L/min. The hemo-
perfusion perfusate was warmed to 37°C by a water bath
and transported to the limb by a peristaltic pump at ap-
proximately 65 mL/min.
For determination of tissue viability, two samples of
the hemoperfusion fluid were taken in hourly intervals
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sample from the median artery and one “venous” sample
from the site of venous outflow. Samples were
centrifuged at 800 g for 10 min and plasma stored fro-
zen at - 20°C until analysis for glucose, lactate and
lactate-dehydrogenase concentrations. Glucose con-
sumption in the tissue was calculated by subtraction of
glucose concentrations in the venous from those deter-
mined in the arterial samples. For lactate production
and LDH activity, values in the arterial were subtracted
from those in the venous samples. Viability criteria were
the same as for the tyrode-perfused limbs.Addition of acetylsalicylic and salicylic acid to the perfusion
fluid
To simulate the systemic administration of ASA (20 mg/
kg bodyweight) to the isolated perfused equine distal
limb, plasma concentrations of ASA and SA from a
study investigating plasma concentrations after intraven-
ous administration in horses [1] were added to the per-
fusion medium. In vivo, ASA would rapidly be converted
to SA via deacetylation by tissue and plasma esterases.
Since the ex vivo model lacks these mechanisms, the re-
spective ASA/SA ratio was imitated in the perfusion
medium as indicated in Table 1. Salicylate concentra-
tions in the perfusion fluid were adjusted to the respect-
ive in vivo plasma concentrations in 30-min-intervals
during the first hour and in 60-min-intervals until the
end of the experiment. Hence, during the first 30 min
after virtual systemic administration of ASA, the perfu-
sion medium contained 100 μg/mL ASA and 50 μg/mL
SA (both Sigma Aldrich, Steinheim, Germany). After 30
min, the perfusion medium was exchanged so that it
contained 40 μg/mL ASA and 125 μg/mL SA and so
forth. Actual ASA and SA concentrations in the perfu-
sion medium were verified by HPLC analysis.
The time point of simulated systemic intravenous ap-
plication was 1 h after the start of perfusion, because the
first 30 min of perfusion were allowed for equilibration
and another 30 min were needed to collect a blank sam-
ple after implantation of the microdialysis probe.Table 1 Simulated intravenous administration of ASA (20
mg/kg bodyweight) in the isolated perfused equine distal
limb according to Broome et al., 2003
Time (h) 0 - 0.5 0.5 - 1 1 - 2 2 - 3 3 - 4 4 - 5 5 - 6 6 - 7
ASA
μg/mL 100 40 5 0 0 0 0 0
SA
μg/mL 50 125 70 35 20 5 5 5
ASA and SA were added to the perfusion fluid in the respective
concentrations indicated below; microdialysis sampling vials were exchanged
with every concentration adjustment.Microdialysis
Determination of relative recovery in vitro
Prior to measuring synovial salicylate concentrations in
the ex vivo model, the relative recovery (RR) of ASA and
SA in equine synovial fluid was established in vitro for
all six microdialysis probes in order to ensure reprodu-
cible drug sampling. Concentric probes of 0.5 mm mem-
brane diameter, 20 kD molecular weight cut-off and a
membrane length of 10 mm were used (CMA 20, CMA
Microdialysis AB, Stockholm, Sweden). For calibration,
the entire probe membrane was placed in a 0.5 mL reac-
tion tube with freshly prepared equine synovial fluid
containing 1, 5, 10, or 15 μg/mL ASA or SA. These con-
centrations had been determined in preliminary experi-
ments (data not shown) in order to obtain an adequate
calibration range.
The microdialysis probe was perfused with phosphate
buffered saline (8 g/L NaCl, 0.2 g/L KCL, 0.2 g/L
KH2PO5, 1.44 g/L Na2HPO4 x 2 H20) at a flow rate of
3 μL/min using a TSE 540063 syringe pump (TSE Sys-
tems, Bad Homburg, Germany). For each concentration,
the dialysate was collected for 60 min following a
10-minute equilibration period. Experiments were
performed at room temperature and repeated on three
consecutive days. The procedure was performed for
ASA and SA. Respective ASA and SA concentrations in
the dialysate were determined with HPLC. Relative re-
covery was calculated for each probe and concentration
by dividing the concentration in the dialysate CDialysate
by the concentration in the synovial fluid CSynovia
(equation 1).
RR ¼ CDialysate=CSynovia in vitro ð1Þ
The average relative recovery for ASA and SA was cal-
culated for each probe in order to determine the re-
spective salicylate concentration in the joint of the
ex vivo model in the following experiments (equation 2).
CSynovia ex vivo ¼ CDialysate=RR ð2Þ
Microdialysis in the isolated perfused equine distal limb
After an equilibration period of 30 min, a calibrated mi-
crodialysis probe was implanted into the fetlock joint of
the isolated perfused equine distal limb via the dorsal
pouch as follows: a stab incision was made through the
skin where probe implantation was planned. A steel nee-
dle was inserted into a split tubing (“introducer”) and in-
troduced into the dorsal pouch of the fetlock joint.
Placement of the needle in the joint was confirmed by
aspiration of synovial fluid. The steel needle was then re-
moved from the introducer and the microdialysis probe
inserted instead. In a last step, the flexible introducer
was pulled out of the joint by splitting it around the
Table 2 Relative recovery (RR) of ASA and SA in equine
synovia for microdialysis probes (CMA 20, CMA
Microdialysis AB, Stockholm, Sweden) in calibration
experiments in vitro









Data are given as mean of 4 different concentrations (1, 5, 10 and 15 μg/mL)
repeatedly measured on 3 consecutive days.





















Figure 1 ASA concentrations in the synovial fluid of the fetlock
joint in the isolated perfused equine distal limb after imitated
systemic administration of 20 mg/kg ASA. Synovial fluid
concentrations were measured using microdialysis and HPLC and
are given as mean ± S.E.M of 6 (tyrode perfusion) or 2
(hemoperfusion) independent experiments. ASA EC50 values for COX
I and COX II (Buntenkötter, 2012) are indicated to assess the anti-
inflammatory effect of the synovial concentrations.
Friebe et al. BMC Veterinary Research 2013, 9:56 Page 4 of 7
http://www.biomedcentral.com/1746-6148/9/56microdialysis probe. The probe was perfused with PBS
at a flow rate of 3 μL/min and sampling vials exchanged
as indicated in Table 1. Samples were frozen at −20°C
immediately after collection until analysis. One probe
was used for each extremity; two probes were used a
second time for the hemoperfusion experiments.
Analytical method and analysis
ASA and SA concentrations were measured in the mi-
crodialysis perfusate using a validated HPLC method
with limits of detection at 53 ng/mL and 84 ng/mL and
limits of quantification at 106 ng/mL and 169 ng/mL for
ASA and SA, respectively. Validation of the method in-
cluded evaluation of the following characteristics: accur-
acy and precision, linearity, and specificity/selectivity.
Validation experiments followed the FDA Guidance for
Bioanalytical Method Validation [18]; all results were in
the range of the recommended limits.
The microdialysis perfusate could be readily analysed
without extraction; 100 μl of each sample were injected
into the isocratic HPLC system (Beckman Coulter
GmbH, Krefeld, Germany) comprising a 126 solvent
module, a 508 autosampler and a 166 Detector. The col-
umn used was a LiChroCARTW 125–4 LiChrospherW
100 RP-18, 5 μm column coupled with a guard column
(LiChroCARTW 4–4; LiChrospherW 100 RP-18, 5 μm;
both Merck KGaA, Darmstadt, Germany). Columns
were kept in a column oven (SpH 99, Spark Holland,
Emmen, Netherlands) at 40°C. Instrument control and
data collection were performed with the software 32
Karat (Beckman Coulter GmbH, Krefeld, Germany).
The mobile phase consisted of HPLC-grade acetonitrile
(Lab-Scan, Gliwice, Poland) and McIlvaine citrate buffer
pH 2.2 (40:60, v/v); flow rate was 1 mL/min and UV de-
tection occurred at 310 nm.
Statistical analysis
Data are expressed as mean ± S.E.M. of independent ex-
periments as specified in individual figure legends. All
graphs were created by GraphPad Prism 5.03 software
(GraphPad Software, Inc., La Jolla, CA, USA).
Results
Tissue viability
Tissue viability requirements were met by all 8 perfused
distal limbs (6 tyrode-perfused and 2 hemoperfused limbs).
The average weight increase was 5.1% after 8 h of perfusion
with tyrode and 8.6% after 5 h of hemoperfusion.
Determination of relative recovery in vitro
Mean values for relative recovery are shown in Table 2;
mean recovery in all probes was 25.2 ± 2.2% for ASA
and 9.1 ± 1.1% for SA (mean ± S.E.M., n = 6).Ex vivo microdialysis in the isolated perfused equine
distal limb - Tyrode
ASA and SA were detectable in all 6 experiments, syn-
ovial fluid concentrations in the fetlock joint are shown
in Figures 1 and 2. ASA reached the highest synovial
concentration of 4 μg/mL shortly after application be-
fore decreasing to approximately 2 μg/mL until the end
of the experiment. Mean ASA concentration in the syn-
ovial fluid over the entire perfusion period was 2 μg/mL.
The drug was detectable until the end of each experi-
ment even though its supply via the perfusion medium
ceased 2 h after “systemic” application, reflecting condi-
tions in vivo.
During the first 5 h after “treatment”, SA concentrations
continuously increased to reach a plateau and maximum
concentration at 17 μg/mL. Mean SA concentration in the




















Figure 2 SA concentrations in the synovial fluid of the fetlock
joint in the isolated perfused equine distal limb after imitated
systemic administration of 20 mg/kg ASA. Synovial fluid
concentrations are given as mean of 2 independent experiments
(hemoperfusion) and mean ± S.E.M. of 6 independent experiments
(tyrode perfusion).
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14 μg/mL. None of the blank samples taken before onset
of drug administration contained any measurable amount
of salicylates.
Ex vivo microdialysis in the isolated perfused equine
distal limb – Hemoperfusion
In the hemoperfused extremities (n = 2), ASA and SA
were detectable in the synovial fluid of the fetlock joint
until the end of the experiment after 4 h (Figures 1 and
2). Mean ASA concentration over the entire perfusion
period was 1.1 μg/mL, synovial concentrations decreased
from the initial maximum concentration of 2 μg/mL to
0.9 μg/mL 3 h after “systemic” administration. SA con-
centration showed an initial increase with a subsequent
decline and ranged from 4 to 7.3 μg/mL, the average be-
ing 5.7 μg/mL. Concentrations of ASA and SA supplied
via the hemoperfusion fluid are displayed in Table 1.
Again, no salicylates could be detected in any of the
blank samples taken before drug administration.
Discussion
Ex vivo model
For each limb, tissue viability was ensured by the criteria
described under the methods section. While establishing
the model, special attention was paid to the integrity of
the synovial membrane [13]. We therefore assumed the
distribution of salicylates into the synovial cavity in the
ex vivo model to be comparable to the in vivo situation.
To get a rough overview of the role of plasma protein
binding on the synovial distribution of ASA and SA, per-
fusion was performed with diluted autologous blood
(mixed with plasma in a ratio of 1:4) in two extremities.
Comparison of the mean synovial fluid concentrations inthe tyrode- and hemoperfused limbs revealed ASA and
SA concentrations to be approximately 50% of the syn-
ovial fluid concentrations in tyrode-perfused limbs. This
difference might be due to the plasma protein binding of
salicylates which is reported to be around 50% [19].
However, pathological changes affecting the perme-
ability of the inner joint capsule are known to alter the
rate of transport of salicylates in man: it has been sug-
gested that e.g. hyperemia and edema formation due to
synovitis in acute osteoarthritis might accelerate salicyl-
ate transport from the bloodstream to the joint, whereas
hyperplastic thickening of the capsule or the synovial
vessels in conditions such as chronic osteoarthritis might
hinder this transport [20]. The possible influence of
these conditions could not be examined in this study be-
cause so far, the model has been established to mirror
conditions only in the healthy limb.
Distribution of salicylates into synovial fluid
In the study presented, the distribution of salicylates into
joint fluid after systemic administration was measured.
Although not frequently used in equine medicine, these
drugs are of peculiar interest because of their special sta-
tus as threshold substances.
The ex vivo model of the isolated perfused equine dis-
tal limb was used to avoid animal experiments. In order
to imitate systemic administration of ASA, salicylate
plasma concentrations in the perfusion fluid of the
ex vivo model were adjusted in accordance with plasma
concentrations reported in an in vivo study. Synovial
concentrations of ASA and SA were monitored in the
fetlock joint of the model using microdialysis.
Even though it has been stated that the transport of
the unbound fraction of a drug through a synovial mem-
brane is a simple diffusion process [21,22], data obtained
from our experiments suggest an accumulation of ASA
and SA in synovial fluid (Figures 1 and 2). This accumu-
lation of salicylates in joint fluid has also been observed
in two studies in man [23,24] and might be explained as
follows: in plasma, ASA is rapidly converted to SA via
deacetylation by endogenous esterases so that SA con-
centrations exceed ASA concentrations shortly after ad-
ministration. In the joint fluid, however, the esterase
activity is much lower than in whole blood or plasma
[23]. Consequently, salicylate concentrations in synovial
fluid remain higher than systemic concentrations be-
cause (a) the continuous deacetylation of ASA to SA in
plasma (imitated in our model by adjusting ASA and SA
concentrations in the perfusion fluid) leads to a constant
supply of SA into the joint and (b) ASA levels in the
joint remain relatively consistent because of the lower
esterase activity in synovial fluid.
To assess any anti-inflammatory effect of the salicy-
lates measured in the synovial fluid of the ex vivo model,
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for ASA in horses. An EC50 value is that plasma concen-
tration at which a half maximal effect is observed [25].
The EC50 values referred to were determined by
Buntenkötter [26] in equine whole blood: COX-I and
COX-II inhibition were assessed by the ability of ASA to
inhibit clot-induced thromboxane B2 production or
prostaglandin E2 production after stimulation with lipo-
polysaccharides, respectively.
ASA concentrations in the synovial fluid measured in
the ex vivo model were still above the ASA EC50 value
for COX I inhibition (0.2 μg/mL) and in the range of the
EC50 value for COX II inhibition (2.2 μg/mL) after the
systemic concentration in the perfusion fluid was below
the plasma threshold of 6.5 μg/mL formulated by the
international equestrian federation FEI (Figure 1).
According to our findings, it might be conceivable to
abusively treat a horse with ASA in order to benefit
from its short half-life and concurrent accumulation in
synovial fluid even though this would clearly contradict
the genuine rationale for SA thresholds, which was
avoiding positive cases solely due to the horse’s diet.
Conclusions
A threshold level for SA in plasma and urine was formu-
lated by horse sport organisations to avoid positive cases
due to the horse’s diet. Data obtained from our ex vivo
study investigating the distribution of salicylates into
joint fluid after systemic administration suggest that
even with systemic concentrations below the threshold,
concentrations in the synovial fluid are in the range of
the EC50 value and may therefore be capable of exerting
an anti-inflammatory effect. These results originate from
an ex vivo setup; nevertheless, they do provide a basis to
further investigate the synovial distribution of systemic-
ally administered salicylates.
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